5
Participants
Start Date
May 31, 2011
Primary Completion Date
September 30, 2013
Study Completion Date
September 30, 2013
entecavir, lamivudine
"entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.~lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
Lead Sponsor
Asan Medical Center
OTHER